Welcome to our dedicated page for Nephros SEC filings (Ticker: NEPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nephros, Inc. (Nasdaq: NEPH) SEC filings page provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. As a public water technology company serving medical, healthcare, commercial, and industrial markets, Nephros uses these filings to report its financial condition, operating results, key risks, and material agreements related to its filtration products, services, and water-quality education activities.
Investors can review annual reports on Form 10-K for a comprehensive discussion of Nephros’ business, including its focus on filtration solutions, programmatic and emergency water management revenue, and segments such as infection control, dialysis water, and commercial applications. Quarterly reports on Form 10-Q provide interim updates on net revenue, gross margin, net income or loss, adjusted EBITDA, cash and cash equivalents, and other balance sheet items.
Current reports on Form 8-K disclose significant events, such as financial results press releases and material contracts. For example, Nephros has filed an 8-K describing a License and Supply Agreement with Medica S.p.A., under which it obtained an exclusive license to market and sell certain filtration products based on Medisulfone ultrafiltration technology and granted Medica rights to make those products under Nephros’ intellectual property. Such filings help clarify how key agreements support the company’s product portfolio and supply arrangements.
On this page, users can also access information related to stockholders’ equity, lease liabilities, and other financial metrics that appear in Nephros’ balance sheets and statements of operations. Stock Titan enhances these documents with AI-powered summaries that highlight important sections, explain technical language, and point out items that may matter most to investors, such as changes in revenue mix, cash position, or contractual commitments. Real-time updates from EDGAR ensure that new NEPH filings, including 10-Ks, 10-Qs, and 8-Ks, are available promptly along with AI-generated insights.
Nephros (NEPH) reported strong Q3 2025 results, driven by higher programmatic activity and service growth. Net revenue rose to $4.764M (up 35% year over year), with gross margin steady at 61%. Operating income improved to $0.314M, and net income reached $0.337M (basic and diluted EPS $0.03).
For the nine months, revenue increased to $14.060M (up 37%), gross margin expanded to 63%, and the company swung to $1.132M in net income from a prior loss. Operating cash flow was $1.415M, lifting cash to $5.171M and working capital to $8.239M. SG&A and R&D rose with higher commissions, bonus accruals, and salaries, while interest income increased.
The company notes customer concentration (top accounts comprised 46% of Q3 revenue) and continues to remediate a previously identified revenue recognition control weakness under ASC 606. As of November 3, 2025, 10,626,683 common shares were outstanding.
Lisa Nettis, a director of Nephros Inc. (NEPH), acquired 13,229 stock options on 08/11/2025 with an exercise price of $4.49 per share. The options convert into 13,229 shares of common stock and have an expiration date of 08/11/2035.
The filing discloses a vesting schedule: 4,410 options vest on each of 6/16/2025 and 6/16/2026, and 4,409 vest on 6/16/2027. The Form 4 was executed by Edward Peilen as attorney-in-fact on 08/13/2025 and lists Nettis as a director.
Nephros, Inc. furnished a press release disclosing its second quarter 2025 financial results and included that press release as Exhibit 99.1 to this Form 8-K. The company explicitly stated the exhibit is furnished, not filed, and therefore is not subject to liability under Section 18 of the Exchange Act nor automatically incorporated by reference into other filings unless expressly stated. The report was signed on behalf of the registrant by the Chief Financial Officer.